28 / 140
Atul Ltd | Annual Report 2012-13
Products
APIs, API Intermediates, Others
Pharmaceuticals Business mainly comprises API intermediates
and a few APIs. The products are used by customers belonging
WR 3KDUPDFHXWLFDO LQGXVWU\ XQGHU ÀYH EURDG WKHUDSHXWLF
categories, namely, cardiovascular, anti-depressant, anti-
diabetic, anti-infective and anti-retroviral. The Business
comprises about 38 products, relatively new to the portfolio
RI SURGXFWV RI WKH &RPSDQ\ ,W LV QRW FXUUHQWO\ HQJDJHG LQ
formulations of APIs.
During the year, sales increased by 23% to
`
314 cr. Sales in
India increased by 27% to
`
FU ([SRUW VDOHV LQFUHDVHG E\
18% to
`
143 cr and formed 46% of the total. Growth on
account of volume was 11%. Sales from new products were
`
8 cr. Atul Bioscience, a 100% subsidiary company, focussed
on production of advanced API intermediates , sales of which
increased from
`
11 cr to
`
27 cr, almost wholly because of
YROXPH LW XQGHUWRRN FDSDFLW\ H[SDQVLRQ LQ ERWK RI LWV SODQWV
:RUOG PDUNHW IRU SKDUPDFHXWLFDOV LV HVWLPDWHG DW
86
EQ FRPSULVLQJ 86
EQ SUHVFULSWLRQ GUXJV
DQG 86 EQ JHQHULF GUXJV DQG LV JURZLQJ DW DERXW
,QGLDQ SKDUPDFHXWLFDOV PDUNHW LV HVWLPDWHG DW 86
EQ
LQFOXGLQJ VDOHV RXW RI ,QGLD DQG LV JURZLQJ DW DERXW
7KHUH DUH DURXQG PDMRU FRPSDQLHV ZKLFK GRPLQDWH WKH
Pharmaceuticals
ZRUOG PDUNHWSODFH LQ SUHVFULSWLRQ GUXJV VSDFH ZLWK VKDUH
of about 67% and around 8 companies in generic drugs
space with share of about 70%.
7KH PDLQ XVHU LQGXVWU\ QDPHO\ +HDOWKFDUH LV JURZLQJ ZHOO
because of increasing awareness about diseases and health.
The Company along with Atul Bioscience will participate in
WKLV JURZWK E\ L ZLGHQLQJ LWV PDUNHW UHDFK LL LQFUHDVLQJ
LWV PDQXIDFWXULQJ HIÀFLHQFLHV LLL JHQHUDWLQJ DQG DGGLQJ
FDSDFLWLHV DQG LY LQWURGXFLQJ QHZ SURGXFWV ,W ZLOO DOVR IRUP
long-term alliances with other companies.
3ULFHV RI PDQ\ SURGXFWV FRPH GRZQ VLJQLÀFDQWO\ LQ D VKRUW
WLPH )OXFWXDWLRQV LQ IRUHLJQ H[FKDQJH ZLOO LPSDFW VDOHV
realisations.